All In Biotech

Drug Trial Radar · NCT00097786

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)

Last checked: Nov 20, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 9,306 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,306

Actual

Start

Jan 2002

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 1, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 50 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Valsartan 160 mg + nateglinide 60 mgDrug

    The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.

  • Valsartan 160 mg + nateglinide placeboDrug

    The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.

  • Nateglinide 60 mg + valsartan placeboDrug

    The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.

  • Valsartan placebo + nateglinide placeboDrug

    The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartanTime frame: Mean patient duration of 4.2 years
  2. Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartanTime frame: Mean patient duration of 5.6 years
  3. Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartanTime frame: Mean patient duration of 5.8 years
  4. Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinideTime frame: Mean patient duration of 4.2 years
  5. Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinideTime frame: Mean patient duration of 5.6 years
  6. Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinideTime frame: Mean patient duration of 5.8 years

Locations

38 sites in 38 countries. Site status is shown where the registry gives one.

  • Site not named

    Multiple Locations, New Jersey

  • Site not named

    Investigative Site, Argentina

  • Site not named

    Investigative Site, Australia

  • Site not named

    Multiple Locations, Austria

  • Site not named

    Investigative Site, Belgium

  • Site not named

    Investigative Site, Brazil

  • Site not named

    Investigative Site, Canada

  • Site not named

    Investigative Site, Chile

  • Site not named

    Investigative Site, China

  • Site not named

    Investigative Site, Colombia

  • Site not named

    Investigative Site, Czechia

  • Site not named

    Investigative Site, Denmark

  • Site not named

    Investigative Site, Ecuador

  • Site not named

    Investigative Site, Finland

  • Site not named

    Investigative Site, France

  • Site not named

    Investigative Site, Germany

  • Site not named

    Investigative Site, Greece

  • Site not named

    Investigative Site, Guatemala

  • Site not named

    Investigative Site, Hong Kong

  • Site not named

    Investigative Site, Hungary

  • Site not named

    Investigative Site, Italy

  • Site not named

    Investigative Site, Malaysia

  • Site not named

    Investigative Site, Mexico

  • Site not named

    Investigative Site, Netherlands

  • Site not named

    Investigative Site, Norway

  • Site not named

    Investigative Site, Peru

  • Site not named

    Investigative Site, Poland

  • Site not named

    Investigative Site, Russia

  • Site not named

    Investigative Site, Singapore

  • Site not named

    Investigative Site, Slovakia

  • Site not named

    Investigative Site, South Africa

  • Site not named

    Investigative Site, Spain

  • Site not named

    Investigative Site, Sweden

  • Site not named

    Investigative Site, Switzerland

  • Site not named

    Investigative Site, Taiwan

  • Site not named

    Investigative Site, Turkey (Türkiye)

  • Site not named

    Investigative Site, United Kingdom

  • Site not named

    Investigative Site, Uruguay

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.